58.31
10 X Genomics Inc stock is traded at $58.31, with a volume of 1.41M.
It is up +3.69% in the last 24 hours and up +32.97% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$56.09
Open:
$55.74
24h Volume:
1.41M
Relative Volume:
0.44
Market Cap:
$7.60B
Revenue:
$638.78M
Net Income/Loss:
$-22.66M
P/E Ratio:
-334.32
EPS:
-0.1744
Net Cash Flow:
$122.18M
1W Performance:
-0.70%
1M Performance:
+32.97%
6M Performance:
+212.35%
1Y Performance:
+335.33%
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TXG
10 X Genomics Inc
|
58.32 | 7.31B | 638.78M | -22.66M | 122.18M | -0.1744 |
|
VEEV
Veeva Systems Inc
|
240.74 | 39.60B | 3.32B | 941.65M | 1.64B | 5.6161 |
|
BTSG
Brightspring Health Services Inc
|
60.55 | 12.21B | 13.65B | 169.86M | 412.12M | 1.0758 |
|
TEM
Tempus Ai Inc
|
51.46 | 9.40B | 1.36B | -302.91M | -219.93M | -1.7182 |
|
HQY
Healthequity Inc
|
102.36 | 8.76B | 1.34B | 230.70M | 440.96M | 2.6695 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
7 Best Genomics Stocks for 2026 and How to Invest - fool.com
5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call - Yahoo Finance
Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital By Investing.com - Investing.com Canada
Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital - Investing.com
A Look at 10x Genomics Inc (TXG) After 3.6% Decline -- GF Value $18.38 vs Price $56.09 - GuruFocus
10x Genomics, Inc.: Financial Data Forecasts Estimates and Expectations | TXG | US88025U1097 - marketscreener.com
10x Genomics director John Stuelpnagel sells $1.15m in shares - Investing.com
10x Genomics director John Stuelpnagel sells $1.15m in shares By Investing.com - Investing.com Australia
10x Genomics Director John R. Stuelpnagel Sells 20,000 Shares in August 2026 SEC Filing - Kalkine Media
Insider Selling: 10x Genomics (NASDAQ:TXG) Director Sells 20,000 Shares of Stock - MarketBeat
10x Genomics (TXG) director John Stuelpnagel sells 20,000 shares in August 11 trades - Stock Titan
Why 10x Genomics (TXG) Is Up 21.7% After Raising 2026 Outlook Despite Q2 Revenue Drop - simplywall.st
10x Genomics $TXG Shares Acquired by Sei Investments Co. - MarketBeat
TXG (TXG) insider schedules sale of common stock and notes prior sale - Stock Titan
US$49.54That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results - simplywall.st
10x Genomics, Inc. (TXG) Stock Analysis: Navigating the High Valuation and Market Dynamics - directorstalkinterviews.com
Is 10x Genomics Inc (TXG) Overvalued After 12.3% Rally? GF Value - GuruFocus
10x Genomics, Inc. (TXG) stock price, news, quote and history - Yahoo Finance UK
10x Genomics (NASDAQ:TXG) Trading Up 7.1%Time to Buy? - MarketBeat
TXG Stock Jumps As Earnings Beat Triggers Analyst Upgrades - StocksToTrade
10X GENOMICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $60 FROM $50 - Bitget
10x Genomics Stock Jumps As Analysts Hike Price Targets - timothysykes.com
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of 10x Genomics Inc Class A – BMV:TXG - TradingView
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX) - The Globe and Mail
TXG Jumps As 10x Genomics Price Targets Surge After Q2 Beat - timothysykes.com
10X Genomics Inc (TXG) Stock News Today - TradingKey
10x Genomics, Inc. Stock 12‑Month Price Target Raised to $47.23, Implies 4% Upside - TradingView
10x Genomics Q2 Earnings Call Highlights - MarketBeat
10x Genomics stock hits 52-week high at 50.36 USD - Investing.com
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up - TradingView
10x Genomics: Atera Sees ‘Extraordinary’ Customer Response As Multiomics Strategy Expands - Pulse 2.0
10X GENOMICS, INC. : JEFFERIES RAISES TARGET PRICE TO $53 FROM $40 - Moomoo
10x Genomics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
10x Genomics (NASDAQ: TXG) grows consumables, ends Q2 with $502M cash - Stock Titan
10x Genomics, Inc. 2026: Revenue $151.04M, EPS ($0.14) — 10-Q Summary - TradingView
10x Genomics $TXG Shares Sold by Janus Henderson Group PLC - MarketBeat
Has 10x Genomics Inc (TXG) Missed Earnings Expectations with Q2 - GuruFocus
10x Genomics (NASDAQ:TXG) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Earnings call transcript: 10x Genomics tops Q2 2026 estimates, shares fall - Investing.com
Transcript : 10x Genomics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
10x Genomics Inc (TXG) Shares Fall 3.9% -- What GF Score of 58 T - GuruFocus
10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations - Yahoo Finance
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics falls 2% despite beating revenue estimates - Investing.com
10x Genomics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
(TXG) 10x Genomics Now Expects 2026 Revenue Range $610M-$630M, vs. FactSet Est of $613.7M - marketscreener.com
Q2 2026 10X Genomics Inc Earnings Call Transcript - GuruFocus
10x Genomics Q2 Swings to Loss, Revenue Falls - marketscreener.com
10x Genomics Q2 2026: Revenue $151.0M, Gross Margin 74%, Raises 2026 Revenue Guide - TradingView
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):